C12N 2770/24111
Flavivirus
Official title: Flavivirus, e.g. yellow fever virus, dengue, JEV
C12N2770/24111 (Flavivirus) appears on 790 US grants and 1,154 published applications in this corpus.
Search patents in C12N- Granted patents
- 790
- Published applications
- 1,154
- Assignees
- 513
- Inventors
- 1,889
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 0 | 0 |
| 1978 | 0 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 1 | 0 |
| 1986 | 0 | 0 |
| 1987 | 1 | 0 |
| 1988 | 1 | 0 |
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 2 | 0 |
| 1992 | 0 | 0 |
| 1993 | 1 | 0 |
| 1994 | 1 | 0 |
| 1995 | 1 | 0 |
| 1996 | 6 | 0 |
| 1997 | 2 | 0 |
| 1998 | 12 | 0 |
| 1999 | 9 | 0 |
| 2000 | 12 | 0 |
| 2001 | 11 | 0 |
| 2002 | 7 | 5 |
| 2003 | 15 | 20 |
| 2004 | 8 | 28 |
| 2005 | 9 | 27 |
| 2006 | 9 | 24 |
| 2007 | 10 | 37 |
| 2008 | 17 | 26 |
| 2009 | 23 | 46 |
| 2010 | 24 | 55 |
| 2011 | 25 | 49 |
| 2012 | 33 | 48 |
| 2013 | 21 | 34 |
| 2014 | 47 | 41 |
| 2015 | 31 | 38 |
| 2016 | 28 | 51 |
| 2017 | 27 | 59 |
| 2018 | 44 | 62 |
| 2019 | 48 | 90 |
| 2020 | 57 | 86 |
| 2021 | 50 | 78 |
| 2022 | 63 | 57 |
| 2023 | 40 | 67 |
| 2024 | 41 | 61 |
| 2025 | 36 | 41 |
| 2026 | 15 | 24 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2770/24134Use of virus or viral component as vaccineIndexing code519
- C12N 2770/24122New viral proteins or individual genes, new structural or functional aspects ofIndexing code412
- C12N 2770/24161Methods of inactivation or attenuationIndexing code167
- C12N 2770/24171Demonstrated in vivo effectIndexing code107
- C12N 2770/24151Methods of production or purification of viral materialIndexing code104
- C12N 2770/24121Viruses as suchIndexing code77
- C12N 2770/24141Use of virus, viral particle or viral elements as a vectorIndexing code70
- C12N 2770/24123Virus like particles [vlp]Indexing code50
All 12 subgroupsShow fewer
Recent patents
- Live-attenuated flaviviruses with heterologous antigens22 Sep 2026US 12,741,991 B2Katholieke Universiteit Leuven
- Compositions and methods for stabilizing flaviviruses with improved formulations15 Sep 2026US 12,734,230 B2Takeda Vaccines, Inc.
- Zika/dengue vaccine and application thereof2 Jun 2026US 12,642,846 B2Institute of Microbiology, Chinese Academy of Sciences
- Methods and compositions for the detection of host protein cleavage by group IV viral proteases21 Apr 2026US 12,607,633 B2The Government of the United States of America, as represented by the Secretary of the Navy
- Methods and compositions for recombinant dengue viruses or vaccine and diagnostic development14 Apr 2026US 12,600,752 B2The University of North Carolina at Chapel Hill
- Systems and Methods for Delivery of Viral Antigens8 Oct 2026US 2026/0306610 A1Veergen Inc.
- Dengue virus serotype-specific modulation of t cell responses8 Oct 2026US 2026/0306621 A1The United States Government as represented by the Department of Veterans Affairs
- A novel non-stoichiometric multi-element adjuvant (nsma) and composition thereof8 Oct 2026US 2026/0306624 A1Magvitae Innovations Inc
- Human antibodies targeting zika virus ns1, ns1 polypeptides and uses thereof10 Sep 2026US 2026/0266820 A1Icahn School of Medicine at Mount Sinai
- Dengue vaccine3 Sep 2026US 2026/0256903 A1VLP Therapeutics, LLC
Most cited
By later US patents
- Method of potentiating an immune response425US 5,075,109 ASouthern Research Institute · 1991
- NYVAC vaccinia virus recombinants comprising heterologous inserts137US 5,494,807 AVirogenetics Corporation · 1996
- Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence128US 5,833,975 AVirogenetics Corporation · 1998
- Hybrid molecules having translocation region and cell-binding region126US 5,668,255 ASeragen, Inc. · 1997
- Process for the production of virus vaccine116US 4,659,569 AKabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo · 1987